Letermovir prophylaxis and early CMV DNAemia after allogeneic hematopoietic stem cell transplantation: a real‑world study from China
Abstract Letermovir is a cytomegalovirus (CMV) prophylactic agent that is not associated with clinically significant myelosuppression. However, real-world data regarding its clinical use in Chinese allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain limited. This study aimed to ass...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Portfolio
2026-04-01
|
| Edice: | Scientific Reports |
| Témata: | |
| On-line přístup: | https://doi.org/10.1038/s41598-026-50851-1 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|